STOCK TITAN

VolitionRX Limited - $VNRX STOCK NEWS

Welcome to our dedicated page for VolitionRX news (Ticker: $VNRX), a resource for investors and traders seeking the latest updates and insights on VolitionRX stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect VolitionRX's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of VolitionRX's position in the market.

Rhea-AI Summary
VolitionRx Limited (VNRX) Announces Strong Financial Results in Q3 2023 and Business Update. The company reported a significant revenue growth of 185% year-over-year and made notable progress with its Nu.Q® NETs pillar, securing FDA agreement and presenting new data at ESICM congress. The company's innovative cancer detection method unveiled at ESMO 2023 received positive feedback, and they are expanding their Nu.Q® Vet Cancer Test globally.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.3%
Tags
-
Rhea-AI Summary
VolitionRx Limited (VNRX) to host conference call on November 15 at 8:30 a.m. U.S. Eastern Time to discuss third quarter 2023 financial and operating results, and provide a business update. Call details and dial-in information provided. President and CEO, Cameron Reynolds, to host the call along with other key executives.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.17%
Tags
-
Rhea-AI Summary
VolitionRx Limited and Veterinary Pathology Group have partnered to launch the Nu.Q® Vet Cancer Test in the UK and Ireland. The test is a groundbreaking tool for early detection and monitoring of cancer in dogs, especially those at higher risk. It is a simple, non-invasive blood test that can be integrated into preventive care plans. Veterinary practices interested in offering the test can find more information at thevpg.co.uk or visit VPG's stand at the London Vet Show.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.47%
Tags
none
Rhea-AI Summary
VolitionRx Limited has unveiled a new cancer detection method at the annual congress of the European Society for Medical Oncology. The method involves the physical isolation of tumor-derived ctDNA fragments from blood, allowing for rapid and cost-effective detection in a routine blood test. The company's proof of concept data shows promising results, with high accuracy in detecting various cancers, including early-stage disease.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.41%
Tags
none
-
Rhea-AI Summary
VolitionRx Limited announces the publication of a clinical paper showing that its Nu.Q® NETs test is a promising biomarker for evaluating disease severity in septic shock patients and could play a role in sepsis prognosis.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-23.86%
Tags
none
-
Rhea-AI Summary
VolitionRx welcomes US Ambassador to its research and manufacturing facilities in Belgium
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.76%
Tags
none
Rhea-AI Summary
VolitionRx to present new data at ESMO 2023 on lung cancer and glioblastoma detection methods.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
VolitionRx publishes report on sepsis management roundtable
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.45%
Tags
none
-
Rhea-AI Summary
VolitionRx Limited is participating in a webinar to present new cancer data on October 21st at ESMO 2023. The webinar will provide deeper insights into the data and outline next steps towards commercialization. Volition is developing blood tests for the early detection of cancer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.7%
Tags
none
Rhea-AI Summary
VolitionRx hosts KOL roundtable on sepsis, discussing challenges and potential treatments, including Volition's Nu.Q® NETs test.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.73%
Tags
none
VolitionRX Limited

NYSE:VNRX

VNRX Rankings

VNRX Stock Data

60.40M
62.70M
23.92%
7.97%
0.6%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
United States of America
HENDERSON

About VNRX

volitionrx is a life sciences company whose goal is to make its non-invasive blood tests for cancer as common and simple to use as existing diabetic and cholesterol tests on similar formats. volitionrx’s development activities are currently centered in belgium with a focus on bringing its revolutionary diagnostic products to market first in europe, then the u.s. and worldwide. you can find more information about volitionrx at our website at www.volitionrx.com, on twitter at www.twitter.com/volitionrx, linkedin at http://www.linkedin.com/company/volitionrx or facebook at www.facebook.com/volitionrx.